Aurinia Pharmaceuticals Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Peter Greenleaf; PEO total compensation $5.86M; PEO compensation actually paid $17.55M; Other NEO average total compensation $2.06M.
- 2024-12-31: PEO total compensation $6.42M; PEO compensation actually paid $7.62M; Other NEO average total compensation $2.21M.
- 2023-12-31: PEO total compensation $10.57M; PEO compensation actually paid $14.92M; Other NEO average total compensation $3.89M.
- 2022-12-31: PEO total compensation $8.84M; PEO compensation actually paid -$8.90M; Other NEO average total compensation $3.28M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Peter Greenleaf | $5.86M | $17.55M | $2.06M | $5.14M | $115.33 | $83.61 | $287.20M | et revenue $283.10M | 2026-04-21 |
| 2024-12-31 | $6.42M | $7.62M | $2.21M | $2.43M | $64.93 | $63.12 | $5.80M | $235.10M | 2026-04-21 | |
| 2023-12-31 | $10.57M | $14.92M | $3.89M | $5.27M | $65.00 | $69.15 | -$78.00M | $175.50M | 2026-04-21 | |
| 2022-12-31 | $8.84M | -$8.90M | $3.28M | -$748.38K | $31.24 | $70.15 | -$108.20M | $134.00M | 2026-04-21 | |
| 2021-12-31 | $1.24M | $16.34M | $718.16K | $4.19M | $165.37 | $92.16 | -$181.00M | $45.60M | 2026-04-21 | |
| 2024-12-31 | Peter Greenleaf | $6.42M | $7.62M | $2.21M | $2.43M | $44.32 | $81.12 | $5.80M | et revenue $235.10M | 2025-04-17 |
| 2023-12-31 | $10.57M | $14.92M | $3.89M | $5.27M | $44.37 | $88.90 | -$78.00M | $175.50M | 2025-04-17 | |
| 2022-12-31 | $8.84M | -$8.90M | $3.28M | -$748.38K | $21.32 | $90.18 | -$108.20M | $134.00M | 2025-04-17 | |
| 2021-12-31 | $1.24M | $16.34M | $718.16K | $4.19M | $112.88 | $118.47 | -$181.00M | $45.60M | 2025-04-17 | |
| 2020-12-31 | $10.68M | -$2.60M | $3.23M | $2.55M | $68.26 | $128.55 | -$102.70M | $50.10M | 2025-04-17 | |
| 2023-12-31 | Peter Greenleaf | $10.57M | $14.92M | $3.89M | $5.27M | $44.37 | $115.42 | -$78.00M | Net Revenue $176.00M | 2024-05-03 |
| 2022-12-31 | $8.84M | -$8.90M | $3.28M | -$748.38K | $21.32 | $113.65 | -$108.00M | $134.00M | 2024-05-03 | |
| 2021-12-31 | $1.24M | $16.34M | $718.16K | $4.19M | $112.88 | $126.45 | -$181.00M | $46.00M | 2024-05-03 | |
| 2020-12-31 | $10.68M | -$2.60M | $3.23M | $2.55M | $68.26 | $126.42 | -$103.00M | $50.00M | 2024-05-03 | |
| 2022-12-31 | Peter Greenleaf | $8.84M | -$8.90M | $3.28M | -$748.38K | $21.32 | $113.65 | -$108.00M | Net Revenue $134.00M | 2023-04-18 |
| 2021-12-31 | $1.24M | $16.34M | $718.16K | $4.19M | $112.88 | $126.45 | -$181.00M | $46.00M | 2023-04-18 | |
| 2020-12-31 | $10.68M | -$2.60M | $3.23M | $2.55M | $68.26 | $126.42 | -$103.00M | $50.00M | 2023-04-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |